Topics

Radiation and Tumor Immune Microenvironment

Tumor Microenvironment Immunogenic Cell Death Cancer Immunotherapy Cell Programmed Death

Radiotherapy is no longer viewed only as a local method for damaging tumor DNA. Irradiated cancer cells and surrounding stromal and immune cells can reshape the tumor immune microenvironment, sometimes converting a poorly inflamed lesion into a site of antigen release and immune priming. This concept links radiation to immunogenic cell death and underlies efforts to combine radiotherapy with immune checkpoint blockade. Observations of immune-mediated regression outside an irradiated field helped motivate the modern search for systemic partners, although such abscopal effects remain uncommon. The response is not uniformly stimulatory: radiation dose, fractionation, tumor genotype, vascular condition, and baseline immune composition can determine whether treatment promotes productive immunity or reinforces suppression. Understanding this duality is central to using radiation as an immune-modulating partner rather than assuming that every irradiated tumor becomes an in situ vaccine[1][2].

Immunogenic radiation injury exposes calreticulin, releases ATP and HMGB1, and generates cytosolic DNA that can activate cGAS-STING signaling and type I interferon programs. These signals recruit and mature dendritic cells, support cross-presentation of tumor antigens, and expand cytotoxic T cells capable of attacking irradiated and distant lesions. Radiation can also increase chemokines, major histocompatibility complex expression, and selected death ligands. The resulting immune response depends on intact antigen-presenting cells and lymphocyte access, not merely on the amount of tumor necrosis. Countervailing effects include lymphocyte depletion, vascular damage, hypoxia, TGF-β production, recruitment of suppressive myeloid cells and regulatory T cells, and adaptive PD-L1 expression. Excessive DNA degradation or poorly chosen fractionation may blunt interferon signaling, illustrating why immunogenicity depends on a defined molecular and temporal context[1][2][3].

The clearest therapeutic application is combination with PD-1, PD-L1, or CTLA-4 blockade, where radiation may supply antigens and inflammatory cues while checkpoint inhibition sustains activated T cells. Trials have explored this strategy in lung cancer, melanoma, head and neck cancer, and other solid tumors, using radiation to a primary tumor, metastasis, or limited set of lesions. Local control is predictable; systemic abscopal responses remain uncommon and should not be treated as an expected consequence. Radiation may also cooperate with STING agonists, vaccines, cytokines, or myeloid-directed therapy. Selecting one lesion for biopsy and another nonirradiated lesion for response assessment can help distinguish local cytotoxicity from systemic immunity. Treatment design must account for target volume and circulating lymphocytes, because broad fields and unfavorable sequencing can impair the very immune cells required for systemic benefit[1][3].

Research now needs biomarker-guided schedules rather than a single universal “immunogenic” dose. Paired tumor and blood sampling can identify interferon activation, antigen-specific T-cell expansion, myeloid remodeling, and mechanisms of failure. Trials should prospectively compare dose and fractionation, specify whether checkpoint blockade begins before, during, or after radiation, and distinguish effects on irradiated versus nonirradiated lesions. Standardized reporting of field size, organ exposure, steroid use, and lymphocyte counts would make studies more comparable. Strategies that protect lymphocytes, normalize vasculature, block TGF-β, or inhibit suppressive myeloid populations may widen the therapeutic window. Radiation can be a powerful organizer of antitumor immunity, but successful translation requires controlling its simultaneous capacity to expose danger, destroy immune effectors, and rebuild an immunosuppressive niche[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
PINK1/Parkin   Oxidative Phosphorylation   STING   IFNAR   Mitochondrial Metabolism   Bacterial   Apoptosis  
Non-Small Cell Lung Cancer   Mycobacterium Tuberculosis Infection   Parkinson's Disease  
192
HY-112693 H-151
H-151 is a potent, selective and covalent antagonist of STING that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease.
STING  
Cancer   Inflammation or Immune System Disease  
168
HY-112906 C-176
C-176 is a selective and blood-brain barrier permeable STING inhibitor. C-176 covalently targets transmembrane cysteine residue 91 and thereby blocking activation-induced palmitoylation of STING.
STING  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
127
HY-13013 SIS3
SIS3 is a potent and selective inhibitor of Smad3 with an IC50 of 3 μM for Smad3 phosphorylation. SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
TGF-beta/Smad  
Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Lung Fibrosis  
113
HY-B0673 Pirfenidone
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
TGF-beta/Smad   CCR  
Colorectal Cancer   Prostate Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
96
HY-L049 Antibacterial Compound Library
Antibacterial agents are a group of materials that fight against pathogenic bacteria. Thus, by killing or reducing the metabolic activity of bacteria, their pathogenic effect in the biological environments will be minimized. The most widely used antibacterial agents exert their effects on bacterial cell wall synthesis, protein synthesis, DNA replication and metabolic pathways. However, resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide. The main mechanisms of resistance are limiting uptake of a drug, modification of a drug target, inactivation of a drug, and active efflux of a drug. Therefore, it is an urgent need to develop new drugs targeted at resistant organisms. MCE offers a unique collection of 1,994 compounds with validated antibacterial activities. MCE antibacterial compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Disease Focused Libraries

92
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L033 Peptidomimetic Library
Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery. MCE Peptidomimetic Library contains 370 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

Structure Classified Libraries

84
HY-L061 Orally Active Compound Library
Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. MCE offers a unique collection of 5,513 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.

Compound Characteristic Classified Libraries

83
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L117 Calcium Channel Blocker Library
Calcium channel blockers (CCBs), also called calcium antagonists are compounds that slow the movement of calcium (Ca2+) through calcium channels into the cells of the heart and blood vessel walls. Calcium causes the heart and arteries to squeeze more strongly. By blocking calcium, calcium channel blockers allow blood vessels to relax and open. So calcium channel blockers are usually used to lower blood pressure, relieve chest pain (angina) and control an irregular heartbeat. MCE supplies a unique collection of 226 calcium channel blockers and antagonists, all of which have the identified inhibitory effect on calcium channel. MCE Calcium Channel Blocker Library is a useful tool for discovery of antihypertensive drugs and cardiovascular disease research.

Signaling Pathway Targeting Libraries

83
HY-L126 Nuclear Receptor Compound Library
Nuclear receptors (NR) are proteins found in cells that sense androgen and thyroid hormones and certain other molecules. They are ligand-activated transcription factors that participate in many aspects of human physiology and pathology, and regulate the expression of various important genes. Nuclear receptors have become one of the main targets in the development of new drug strategies, providing a unique type of receptors for studying a variety of human diseases, such as breast cancers, skin disorders and diabetes. 13% of U.S. Food and Drug Administration (FDA) approved drugs target nuclear receptors. MCE supplies a unique collection of 1,092 nuclear receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on nuclear receptor. MCE Nuclear Receptor Library is a useful tool for drugs research related to cancer, skin disease and diabetes.

Signaling Pathway Targeting Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L171 Anti-Hematopathy Compound Library
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Disease Focused Libraries

83
HY-L179 Radiosensitizer Library
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells. MCE designs a unique collection of 39 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Compound Characteristic Classified Libraries

83
HY-L186 Neurotransmitter Compound Library
Neurotransmitters are chemical messengers that allows a neuron's electrical signal to pass to a postsynaptic neuron or effect target. Neurotransmitters include amino acids, monoamines, and peptides, while other neurotransmitters are composed of metabolites such as nitric oxide and carbon monoxide. The function of neurotransmitters is closely related to the disease of life, helping to regulate the body's heartbeat, blood pressure, breathing, sleep, aging and muscle activity. Therefore, research based on neurotransmitters can help to increase human understanding of diseases. MCE collects and organizes 54 neurotransmitters and is a tool library for drug screening and mechanism research.

Compound Characteristic Classified Libraries

83
HY-L194 Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
Heat-clearing and detoxification is a specific treatment method in the research of traditional Chinese medicine (TCM), which is clinically used to treat infectious diseases with remarkable effect. Over the past decades, the research of heat-clearing and detoxification treatment has been one of the most active fields of combining traditional Chinese and western medicines, and has made remarkable achievements. Nowadays, the application field of heat-clearing and detoxification traditional Chinese medicine is not only limited to antibacterial and antiviral, but also has made progress in the research fields of anti-inflammatory reaction, anti-endotoxin, anti-peroxidative damage, anti-inflammatory cytokines, enhancement of immune function, protection of cellular organelles, and maintenance of calcium homeostasis. In addition to this, clearing heat and removing toxins has also made significant research progress in non-infectious diseases, for example, in tumors, cardiovascular diseases, renal diseases, blood diseases, geriatrics, and diabetes, all of which have shown good curative effect. MCE can supply 1,282 monomer component from more than a hundred sources of heat-clearing and detoxification TCM, which can be used in TCM studies, drug development and mechanism-based studies.
83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Metabolism Focused Libraries

83
HY-L247 Environmental Pollutant Compound Library
Environmental pollution refers to the process where human activities release harmful chemicals or energy (such as industrial waste, pesticides, and plastic particles) into the natural environment at a rate that exceeds the ecosystem's capacity for self-purification, leading to deterioration in the composition or state of the atmosphere, water bodies, and soil. Environmental pollution is not only a direct threat to biodiversity but also ultimately impacts human health through the bioaccumulation effect of the food chain. Therefore, the accurate identification and dynamic monitoring of pollutants constitute the scientific cornerstone for formulating environmental policies, assessing ecological risks, and promoting green chemistry transformation. MCE features a collection of 296 environmental pollutants, covering categories such as air pollutants, water pollutants, and pesticides, for research in the field of environmental chemistry.

Compound Characteristic Classified Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
STING   IFNAR   Influenza Virus  
Prostate Cancer   Viral Infection   Autoimmune Disease   Non-Small Cell Lung Cancer  
80
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-100347A SRI-011381 hydrochloride
SRI-011381 hydrochloride is an orally active TGF-β signaling agonist, exhibits neuroprotective effects, with blood-brain barrier permeability.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-100347 SRI-011381
SRI-011381 is an orally active TGF-β signaling agonist, exhibits neuroprotective effects.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-112921A diABZI STING agonist-1
diABZI STING agonist-1 is a tautomerism of diABZI STING agonist-1 tautomerism (HY-112921). diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
STING  
Cancer   Inflammation or Immune System Disease   Neurodegenerative Disease  
52
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-136927 MSA-2
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.
STING  
Cancer   Inflammation or Immune System Disease  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-16268 Kartogenin
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research.
TGF-beta/Smad  
Inflammation or Immune System Disease   Liver Cancer  
33
HY-K1042 AntiFade Mounting Medium

MCE AntiFade Mounting Medium can slow the fluorescence quenching of various common fluorescent dyes with simple operation and good anti-fluorescence quenching effect.

Cell Biology Cell Analysis AntiFade Mounting Medium

32
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-13902 Berzosertib
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer.
ATM/ATR   Apoptosis   STING   Caspase  
Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection   Obesity  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-12212 Omaveloxolone
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Keap1-Nrf2   STING   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Lung Fibrosis  
26
HY-164388 Z-VAD
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation.
Caspase   Apoptosis   Autophagy   Necroptosis  
Digestive System Disease   Lung Cancer   Breast Cancer   Neurodegenerative Disease   Digestive System Inflammation   Cardiovascular Disease  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-N1584 Halofuginone
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
DNA/RNA Synthesis   TGF-beta/Smad   Parasite   Sodium Channel   Calcium Channel  
Inflammation or Immune System Disease   Ovarian Cancer   Parasitic Infection   Pulmonary Hypertension  
22
HY-W000450 5-Aminolevulinic acid
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) is an orally active heme precursor. 5-Aminolevulinic acid promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid can be applied to the research of septic shock, melanoma, and cancer radiotherapy.
Reactive Oxygen Species (ROS)  
Gastric Cancer   Bladder Cancer  
21
HY-N0305 5-Aminolevulinic acid hydrochloride
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) hydrochloride is an orally active heme precursor. 5-Aminolevulinic acid hydrochloride promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid hydrochloride enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid hydrochloride selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid hydrochloride can be applied to the research of septic shock, melanoma, and cancer radiotherapy.
Reactive Oxygen Species (ROS)  
Metabolic or Endocrine Disease   Colorectal Cancer   Melanoma   Digestive System Inflammation   Glioblastoma   Alzheimer's Disease  
21
HY-12326 c-di-AMP
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-12326B c-di-AMP diammonium
c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-12326A c-di-AMP disodium
c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-N0439 Asiaticoside
Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
p38 MAPK   TGF-beta/Smad   Reactive Oxygen Species (ROS)   Apoptosis   Endogenous Metabolite  
Digestive System Disease   Lung Cancer   Neurodegenerative Disease   Pain   Digestive System Inflammation   Cardiovascular Disease  
19
HY-116084 Trimethylamine N-oxide
Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.

Source: Host intestinal bacteria

Drug Metabolite   NOD-like Receptor (NLR)   Reactive Oxygen Species (ROS)   TGF-beta/Smad   Endogenous Metabolite  
Liver Cancer   Depression   Autoimmune Disease   Cardiovascular Disease  
12
HY-N0294 Protocatechuic acid
Protocatechuic acid is a phenolic compound which exhibits neuroprotective effect.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease  
10
HY-W020044 DL-alpha-Tocopherol
DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.
Ferroptosis   DNA/RNA Synthesis   Apoptosis  
Digestive System Disease   Digestive System Inflammation  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N2155 Tubuloside A
Tubuloside A is a phenylethanoid glycoside with antioxidative effect and hepatoprotective activity.
Others  
Metabolic or Endocrine Disease  
4
HY-P70700A Sting1/TMEM173 Protein, Human (N-His-Sumo)
The TMEM173 protein acts as a promoter of innate immune signaling, acting as a sensor of bacterial and viral cytoplasmic DNA, ultimately promoting the production of type I interferons (IFN-α and IFN-β). This innate immune response is triggered in response to the delivery of non-CpG double-stranded DNA from viruses and bacteria into the cytoplasm. Sting1/TMEM173 Protein, Human (N-His-Sumo) is the recombinant human-derived TMEM173 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Species: Human; Source: E. coli

4
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Apoptosis   p38 MAPK  
Melanoma  
3
HY-P99241 Ponsegromab
Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively. Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels. Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer.

Species: Human

TGF-beta/Smad   TGF-β Receptor  
Breast Cancer   Non-Small Cell Lung Cancer  
3
HY-N8107 Matairesinol monoglucoside
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection.
STING   IFNAR   HBV  
Hepatitis B Virus Infection  
2
HY-N6985 Baccatin III
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment.
Others  
Breast Cancer   Lung Fibrosis  
2
HY-P99051 Tinurilimab
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
2
HY-112624 Dextran
Dextran (Dextran 40) has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
2
HY-W016562 Hippuric acid
Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research. .
Endogenous Metabolite   Keap1-Nrf2   MMP   Reactive Oxygen Species (ROS)   TGF-beta/Smad  
Colorectal Cancer   Cardiovascular Disease   Colitis   Hyperuricemia   Rheumatoid Arthritis  
2
HY-P70700 Sting1/TMEM173 Protein, Human (Sumo-His)
The TMEM173 protein acts as a promoter of innate immune signaling, acting as a sensor of bacterial and viral cytoplasmic DNA, ultimately promoting the production of type I interferons (IFN-α and IFN-β). This innate immune response is triggered in response to the delivery of non-CpG double-stranded DNA from viruses and bacteria into the cytoplasm. Sting1/TMEM173 Protein, Human (Sumo-His) is the recombinant human-derived TMEM173 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

2
HY-P1181 Pam2CSK4
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-N10020 Patulitrin
Patulitrin has scavenging effect in the DPPH radical. Patulitrin inhibits soybean lipoxygenase. Patulitrin also has antihypertensive effect. Patulitrin is an antioxidant flavonoid that can be isolated from Anthemis tinctoria.
Lipoxygenase   Free Radical Scavengers  
Inflammation or Immune System Disease  
1
HY-N0620 Mulberroside C
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease.
HCV   Enterovirus   PERK   Calcium Channel   P-selectin   HCN Channel   Ras   ERK   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Hepatitis C Virus Infection   Staphylococcus Aureus Infection  
1
HY-10087S Navitoclax-d8
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
Isotope-Labeled Compounds   Bcl-2 Family   Apoptosis   Survivin   TGF-β Receptor  
Ovarian Cancer   Triple-Negative Breast Cancer   Acute Lymphoblastic Leukemia   Platelet Disease  
1
HY-N4312 Bryodulcosigenin
Bryodulcosigenin is an extract of the roots of Bryoniadioica with anti-inflammatory effect.
Others  
Inflammation or Immune System Disease  
1
HY-P1328 TAT-14
TAT-14 is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect. TAT-14 has no effect on Nrf2 mRNA expression, but increases Nrf2 protein level due to targeting the Nrf2 binding site on Keap1.
Keap1-Nrf2  
1
HY-N2616 Vomicine
Vomicine modulates cGAS-STING-TBK1 signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds.
STING  
Cancer   Inflammation or Immune System Disease  
1
HY-P990181 Anti-Mouse myeloperoxidase/MPO Antibody (6G4)
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV).

Species: Mouse

Glutathione Peroxidase   STING  
Inflammation or Immune System Disease  
1
HY-N0023 Cistanoside A
Cistanoside A is a phenylethanoid isolated from Cistanche deserticola, reduces NO accumulation, but shows no effect on iNOS mRNA, iNOS protein levels or iNOS activity. Anti-inflammatory effect.
NO Synthase  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Lung Fibrosis  
1
HY-N0819 Raddeanin A
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Cancer Immunology   Digestive System Inflammation   Non-Small Cell Lung Cancer   Immunotherapy for Melanoma   Alzheimer's Disease  
1
HY-P1181A Pam2CSK4 TFA
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-P9928A Alirocumab (anti-PCSK9)
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.

Species: Human

PCSK9   NOD-like Receptor (NLR)   Keap1-Nrf2   HMG Family   NF-κB   CX3CR1  
Cancer   Blood or Cardio-cerebrovascular Disease  
1
HY-121608 Lumiflavin
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
Fluorescent Dye   Notch  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-P9928 Alirocumab
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.

Species: Human

PCSK9   NOD-like Receptor (NLR)   Keap1-Nrf2   HMG Family   NF-κB   CX3CR1  
Inflammation or Immune System Disease   Atherosclerosis  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P80940 STING Antibody
STING Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to STING.

Host: Rabbit; Reactivity: Human, Mouse

Polyclonal Antibodies Primary Antibodies

1
HY-P80783A PGC1 alpha Antibody (YA7180)
PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-K2023 In vivo OptiLNP RNA Transfection Reagent (Local Effect)

MCE In vivo OptiLNP RNA Transfection Reagent (Local Effect) is a ready-to-use transfection reagent based on LNP technology. It is designed for the efficient transfection of mRNA and short-chain RNA in experimental animals. The RNA functions locally.

Cell Biology Cell Culture Cell Transfection

1
HY-W756829 Omaveloxolone-d3
Omaveloxolone-d3 (RTA 408-d3) is the deuterated-labeled Omaveloxolone (HY-12212). Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Isotope-Labeled Compounds   Apoptosis   STING   Keap1-Nrf2  
Cancer   Inflammation or Immune System Disease  
/
HY-19825 Rebeccamycin
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.

Source: the mycelium

Topoisomerase   ADC Payloads   Antibiotic  
/
HY-184535 PDIC-DPC
PDIC-DPC is a HMGA1 inhibitor and lung-targeting agent. PDIC-DPC upregulates STING expression and enhances STING-mediated immune signaling. PDIC-DPC inhibits the TGFβ-Smad pathway and activates AMPK. PDIC-DPC forms nanocomplexes with fibrinogen β chain and vitronectin, and achieves lung-specific accumulation by binding to pulmonary endothelial receptors. PDIC-DPC reverses established pulmonary fibrosis, reduces collagen deposition, restores alveolar structure, improves pulmonary function, and inhibits in situ ESCC growth. PDIC-DPC can be used for the research of esophageal squamous cell carcinoma and idiopathic pulmonary fibrosis.
HMG Family   STING   TGF-beta/Smad   AMPK  
Squamous Cell Carcinoma   Lung Fibrosis  
/
HY-110382S Cyclic-di-GMP-13C20,15N10 disodium
13C20,15N10-Cyclic di-GMP (13C20,15N10-c-di-GMP) is 13C and 15N labeled Cyclic-di-GMP (disodium). Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
Isotope-Labeled Compounds   STING   Endogenous Metabolite  
Cancer  
/
HY-W250311 DL-Aspartic acid hemimagnesium salt
DL-Aspartic acid (hemimagnesium salt is DL-aspartic acid salt. DL-aspartic acid hemimagnesium salt is a commonly used food supplement and food additive, because it can promote the synthesis of protein in the human body, and has a positive effect on the nervous system and The production of cardiovascular system has a certain protective effect. In addition, due to some chemical reactions in the industry, DL-aspartic acid semi-magnesium salt can also be obtained.
Biochemical Assay Reagents  
/
HY-P990755A Pamvatamig (FUT8-KO)
Pamvatamig (FUT8-KO) is an anti-EGFR/MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.

Species: Human

EGFR  
Cancer  
/
HY-P11128 Mastoparan-V1
Mastoparan-V1 is a peptide belonging to the Mastoparan family. Mastoparan-V1 exhibits modest mast cell degranulation activity, with EC50 of 130.24 μM in RBL-2H3 cells. Mastoparan-V1 can be used for the study of allergic reactions induced by wasp stings.
Others  
/
HY-P0100 AHK
AHK is a bioactive peptide with antioxidant effect and has been reported used as a cosmetic ingredient.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease  
/
HY-P992020 Anti-HMG1 Antibody
Anti-HMG1 Antibody is an anti-HMG1 antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

Species: Human

HMG Family  
/
HY-B0002BS1 Ondansetron-d3
Ondansetron-d3 is the deuterium labeled Ondansetron (HY-B0002B ). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy.
5-HT Receptor   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-D1173 Acid blue 113
Acid blue 113 is an azo dye whose staining effect is effectively removed by nanoscale zero-valent iron (NZVI) particles.
Fluorescent Dye  
/
HY-P10590 Talogreptide mesaroxetan
Talogreptide mesaroxetan is a diagnostic imaging agent, with antineoplastic effect.
Fluorescent Dye  
Cancer  
/
HY-P10092 SP6
SP6 exertes an antihypertensive effect through vascular NO regulation.
Akt   PI3K   NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-W020044S1 DL-alpha-Tocopherol-d9
DL-alpha-Tocopherol-d9 is the deuterium labeled DL-alpha-Tocopherol. DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.
Ferroptosis  
/
HY-P4259 Hirullin P18
Hirullin P18 is a potent thrombin inhibitor. Hirullin P18 has an anticoagulant effect.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-W740485 Hexamidine-d12
Hexamidine-d12 is the deuterium labeled Hexamidine. Hexamidine has amoebicidal effect that can be used for the research of Acanthamoeba keratitis.
Isotope-Labeled Compounds   Parasite  
Infection  
/
HY-P11205 Cys-PKHB1
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-D1121 Acid black 24
Acid black 24 is a black agent whose staining effect is effectively removed by nanoscale zero-valent iron (NZVI) particles. The maximum unit removal capacity is 609.4 mg of dye per gram of NZVI.
Fluorescent Dye  
/
HY-P991949 EV1007
EV1007 is a fully human antibody with a neutralizing effect on GM-CSF activity. EV1007 can be used for the research of autoimmune diseases.

Species: Human

c-Fms  
Autoimmune Disease  
/
HY-P5224 Lipospondin
Lipospondin is a bioactive peptide with anti-wrinkl effect and has been reported used as a cosmetic ingredient.
Others  
/
HY-160263S Anticancer agent 186
BET-IN-22 (compound 231) has anti-tumor effect.
Isotope-Labeled Compounds  
Cancer  
/
HY-P5711 NEMURI
NEMURI is an antimicrobial peptide with sleep-promoting effect.
Bacterial  
Infection  
/
HY-181546 Ibt-DOX
Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research.
Btk   PERK   Syk   HMG Family  
Leukemia/Lymphoma/Myeloma  
/
HY-P1617 LY 190388
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced.
Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P5887 Tertiapin-RQ
Tertiapin-RQ is an inward rectifier K+ channel blocker peptide with antidepressive effect.
Potassium Channel  
Neurological, Eye or Ear Disease  
/
HY-P992340 CTB006
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   TNF Receptor  
Colorectal Cancer  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P990038 Eurestobart
Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors.

Species: Human

NTPDase  
Neurological, Eye or Ear Disease  
/
HY-B0002BS2 Ondansetron-13C,d3
Ondansetron-13C,d3 is the 13C- and deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy.
Isotope-Labeled Compounds   5-HT Receptor  
Neurological, Eye or Ear Disease  
/
HY-U00315S Gidazepam-d5
Gidazepam-d5 is a deuterium labeled Gidazepam. Gidazepam is an agonist of GABA receptor channels (GABA RCs), and has anticonvulsant effect.
GABA Receptor  
Neurological, Eye or Ear Disease  
/
HY-N12507 Eupenicisirenin C
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells.

Source: mangrove sediment-derived fungus Penicillium sp. SCSIO 41410.

STING   NF-κB  
/
HY-135393S Sulfadimethoxypyrimidine-d4
Sulfadimethoxypyrimidine-d4 is a deuterium labeled Sulfadimethoxypyrimidine. Sulfadimethoxypyrimidine is a sulfonamide antibiotic with a broad-spectrum antibacterial effect.
Isotope-Labeled Compounds   Bacterial  
Bacterial Infection  
/
HY-134181 Tremella polysaccharide, MW>1000000, cosmetic grade
Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-D1036A Basic red 18
Basic red 18 is a basic red dye whose dyeing effect can be removed by nanoclay adsorbent.
Fluorescent Dye  
/
HY-P992339 cT84.66
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.

Species: Human

Radionuclide-Drug Conjugates (RDCs)  
Colorectal Cancer  
/
HY-P992473 TAS266
TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease   Pancreatic Cancer  
/
HY-P991403 BC011
BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.

Species: Human

TNF Receptor  
Cancer  
/
HY-P10371 PKHB1
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.
Reactive Oxygen Species (ROS)   Thrombopoietin Receptor   Mitochondrial Metabolism   HSP   HSV   CD47  
Inflammation or Immune System Disease   Breast Cancer   Acute Lymphoblastic Leukemia   HSV Infection  
/
HY-101445G Trolox (GMP)
Trolox (GMP) is Trolox (HY-101445) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Trolox is an analogue of vitamin E with a powerful antioxidant effect. Trolox is also a powerful inhibitor of membrane damage.
Reactive Oxygen Species (ROS)   Ferroptosis   Apoptosis  
Cancer  
/
HY-N3226 Myricananin A
Myricananin A is a colorless needle that has inhibitory effect on iNOS.
NO Synthase  
Inflammation or Immune System Disease  
/
HY-P992005A DS-1055a (FUT8-KO)
DS-1055a (FUT8-KO) is an anti-human GARP antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. DS-1055a (FUT8-KO) can effectively eliminate GARP-positive regulatory T cells in the tumor microenvironment and activate effector T cells. DS-1055a (FUT8-KO) has anti-tumor activity and can be used in cancer research (such as colon cancer).

Species: Human

Transmembrane Glycoprotein  
Colorectal Cancer  
/
HY-P992519 PF-06940434
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
Integrin   TNF Receptor   TGF-β Receptor  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Squamous Cell Carcinoma  
/
HY-Z15849 Caffeoylmalic acid
Caffeoylmalic acid is an orally active hydroxycinnamoyl-malate ester found in stinging nettle (Urtica dioica). Caffeoylmalic acid exhibits anti-diabetic, anti-inflammation and anti-oxidant effects. Caffeoylmalic acid shows cytotoxicity to cancer cells. Caffeoylmalic acid can be used for the researches of cancer, inflammation and metabolic disease, such as colon cancer and diabetes.
Others  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D1144 Acid blue 260
Acid blue 260 is an azo dye whose staining effect is effectively removed by multi-walled carbon nanotubes (MWCNTs). At 298 K, the adsorption capacity of MWCNT is 233.34 mg/g; and increases with the increase of dye concentration and temperature.
Fluorescent Dye  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-W020044S DL-alpha-Tocopherol-13C3
DL-alpha-Tocopherol-13C3 is the 13C-labeled DL-alpha-Tocopherol. DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.
Isotope-Labeled Compounds   Ferroptosis  
/
HY-W010108 DL-Glutamic acid hydrate
DL-Glutamic acid hydrate is a racemic amino acid mixture and an antibacterial agent. DL-Glutamic acid hydrate reduces RNA and DNA levels, with a more significant effect on RNA. DL-Glutamic acid hydrate inhibits cell division of Rhodospirillum rubrum.
Endogenous Metabolite   DNA/RNA Synthesis   Bacterial  
Bacterial Infection  
/
HY-145552S Azilsartan mepixetil-d5
Azilsartan mepixetil-d5 (QR-01019-d5) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A).
Isotope-Labeled Compounds   Angiotensin Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-D0371 Acid blue 62
Acid blue 62 is an acid dye whose staining effect can be removed by sepiolite
Fluorescent Dye  
/
HY-N0819R Raddeanin A (Standard)
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Reference Standards   Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-106333 Irtemazole
Irtemazole is an orally active antifungal agent. Irtemazole possesses uricosuric effect. Irtemazole is used in the research for blastomycosis, histoplasmosis, and aspergillosis.
Fungal  
Infection   Inflammation or Immune System Disease  
/
HY-N8829R (-)-Myrtenol (Standard)
(-)-Myrtenol (Standard) is the analytical standard of (-)-Myrtenol (HY-N8829). This product is intended for research and analytical applications. (-)-Myrtenol is the enantiomer of Myrtenol. (-)-Myrtenol has anti-anxiety effect. (-)-Myrtenol has the characteristics of gastric cell protection.
Biochemical Assay Reagents   Reference Standards  
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Reference Standards   Apoptosis   p38 MAPK  
Melanoma  
/
HY-N2616R Vomicine (Standard)
Vomicine (Standard) is the analytical standard of Vomicine. This product is intended for research and analytical applications. Vomicine modulates cGAS-STING-TBK1 signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds.
Reference Standards   STING  
Inflammation or Immune System Disease  
/
HY-D0402 Acid black 26
Acid black 26 is a black agent whose coloring effect can be removed by adsorbents such as zeolites.
Fluorescent Dye  
/
HY-W342458 Betamethasone 17-Propionate
Betamethasone 17-Propionate is a compound used to study its effects on endotoxin-induced uveitis in rats. It has the activity of inhibiting the infiltration of cells into the aqueous humor in endotoxin-induced uveitis by eye drops and systemic administration at a certain dose. However, its inhibitory effect is relatively weak compared with some other compounds. At the same time, the dose for systemic administration is 1mg/kg. In addition, Betamethasone 17-Propionate has a weaker inhibitory effect on the release of IL-8 from rat peritoneal exudate cells in an in vitro interleukin-8 (IL-8) release assay than betamethasone. Moreover, the simultaneous addition of betamethasone dipropionate and betamethasone 17-Propionate reduces the inhibitory effect of betamethasone on cell infiltration and IL-1β gene expression.
Biochemical Assay Reagents  
/
HY-P99469 Bentracimab
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor.

Species: Human

Others  
Metabolic or Endocrine Disease  
/
HY-148775 PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
Biochemical Assay Reagents  
Bacterial Infection   Glioblastoma  
/
HY-W076042 Cesibor dihydrate
Cesibor dihydrate is an additive salt used in ion-selective electrodes (ISEs) and micro ion-selective field effect transistors (μ-ISFETs) to enhance or modulate their selective responses to specific ions.
Biochemical Assay Reagents  
/
HY-P991525 2141-V11
2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8+ T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma.

Species: Human

Fc Receptor (FcR)  
Breast Cancer   Bladder Cancer   Melanoma   Glioma  
/
HY-W654210 Glycopyrrolate-d3 bromide
Glycopyrrolate-d3 (bromide) is deuterium labeled Glycopyrrolate. Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases.
Isotope-Labeled Compounds   mAChR  
Cancer  
/
HY-W012980S1 Isovaleric acid-13C
Isovaleric acid-13C is the 13C labeled Isovaleric acid. Isovaleric acid is a natural fatty acid and known to effect on neonatal death and possible Jamaican vomiting sickness in human.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P11205A Cys-PKHB1 TFA
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-N14001 Naamidine J
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.

Source: Pericharax heteroraphis

TNF Receptor   Interleukin Related   Arginase   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-D0164 Naphthol AS-BI
Naphthol AS-BI is a substrate of β-glucuronidase and produces a bright red effect after staining biological tissues.
Fluorescent Dye   β-glucuronidase  
/
HY-P10449 M2 Peptide
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P99179 CTX-2026
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer.

Species: Human

Others  
Cancer  
/
HY-B0002BS Ondansetron-d5
Ondansetron-d5 is the deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy.
5-HT Receptor   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-N8829 (-)-Myrtenol
(-)-Myrtenol is the enantiomer of Myrtenol. (-)-Myrtenol has anti-anxiety effect. (-)-Myrtenol has the characteristics of gastric cell protection.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-W012980S Isovaleric acid-d9
Isovaleric acid-d9 is the deuterium labeled Isovaleric acid. Isovaleric acid is a natural fatty acid and known to effect on neonatal death and possible Jamaican vomiting sickness in human.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P3445A Anrikefon acetate
Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect.
Opioid Receptor  
Depression   Pain  
/
HY-P2920 Protamine from salmon
Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro.
Biochemical Assay Reagents   Thrombin   Bacterial  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-134181A Tremella polysaccharide, MW<1000000, cosmetic grade
Tremella polysaccharide, MW<1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-D0003 Methyl Blue
Methyl blue belongs to the group of triaminotriphenylmethane dyes. Methyl blue is widely used as antiseptic dye in polychrome staining method and has applications in histological and microbiological staining solutions. Methyl blue has been used as a model to study the effect of various catalysts on photodegradation of dyes.
Environmental Pollutants   Bacterial  
Infection  
/
HY-P99623 Flotetuzumab
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

Species: Human

CD3  
Cancer  
/
HY-P99947 Rimteravimab
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2.

Species: Virus

SARS-CoV  
Infection  
/
HY-P990651 PY314
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.

Species: Human

TREM receptor  
Ovarian Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer  
/
HY-P990961 Palverafusp alfa
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N1984 Artemisic acid
Artemisinic acid (Qing Hao acid) is a sesquiterpene that can be isolated from Artemisia annua L. Artemisinic acid is also an important precursor for the synthesis of Artemisinin (HY-B0094). Artemisinic acid has various pharmacological activities, such as antimalarial activity, antitumor activity, antipyretic effect, antibacterial activity, allelopathic effect, and anti-adipogenic effect.
JNK   Interleukin Related  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-129071 Vindesine sulfate
Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo.
Microtubule/Tubulin  
Lung Cancer  
/
HY-159062 Goji Extract
Goji Extract is a natural product with anti-aging, antioxidant, and neuroprotective effects. The antioxidant effect of Goji Extract has a positive impact on erectile dysfunction and can be used in research to improve erectile function.
Biochemical Assay Reagents   NO Synthase  
Neurological, Eye or Ear Disease  
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
PACAP Receptor  
Cancer   Neurological, Eye or Ear Disease   Immunomodulation  
/
HY-P1680 Astin C
Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers.
STING   HSV  
Cancer   Inflammation or Immune System Disease   Viral Infection  
/
HY-P9S0008 Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-W020780 mPEG5000-Mal
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
Biochemical Assay Reagents  
/
HY-P706005 Sting1/TMEM173 Protein, Human (P. pastoris, His)
The TMEM173 protein acts as a promoter of innate immune signaling, acting as a sensor of bacterial and viral cytoplasmic DNA, ultimately promoting the production of type I interferons (IFN-α and IFN-β). This innate immune response is triggered in response to the delivery of non-CpG double-stranded DNA from viruses and bacteria into the cytoplasm. Sting1/TMEM173 Protein, Human (P. pastoris, His) is the recombinant human-derived TMEM173 protein, expressed by P. pastoris , with C-6*His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P80350 STING Antibody (YA048)
STING Antibody (YA048) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STING.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86617 STING Antibody (YA6309)
STING Antibody (YA6309) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STING.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85326 PGC1 alpha Antibody (YA5018)
PGC1 alpha Antibody (YA5018) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to PGC1 alpha.

Host: Rabbit; Reactivity: Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83728 PGC1 alpha+beta Antibody (YA3458)
PGC1 alpha+beta Antibody (YA3458) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha+beta.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810540 Phospho-STING (Ser366) Antibody (YA9809)
Phospho-STING (Ser366) Antibody (YA9809) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-STING (Ser366).

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80783AA PGC1 alpha Antibody (YA7180)(PBS only)
PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K0315A Hematoxylin-Eosin Staining Kit (Including Differentiation and Bluing Solutions)

MCE Hematoxylin-Eosin Staining Kit (Including Differentiation and Bluing Solutions) contains staining solutions, differentiation solution, and bluing solution. Through optimized formulations, it helps to adjust the staining effect, ensuring proper staining intensity and further improving experimental accuracy.

Cell Biology Cell Analysis Staining Kit

/
HY-K2022 In vivo OptiLNP RNA Transfection Reagent (Systemic Effect)

MCE In vivo OptiLNP RNA Transfection Reagent (Systemic Effect) is a ready-to-use transfection reagent based on LNP technology. It is designed for the efficient transfection of mRNA and short-chain RNA in experimental animals. The RNA functions systemically.

Cell Biology Cell Culture Cell Transfection

/

Keywords

radiotherapy | tumor immune microenvironment | immunogenic cell death | STING | immune checkpoint blockade | abscopal effect